发表论文（按年度）：
Publications
ORCID iD: https://orcid.org/0000-0003-0381-6796
已发表的主要论著目录：
1. Zhang MN, Xu B, Li N, Zhang R, Zhang QQ, Shi XR, Xu KT, Xiao J, Chen D, Niu JD, Shi YH, Fang Q*. Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-lasting Peripherally Restricted Antinociception with Diminished Side Effects. Journal of Medicinal Chemistry 2021; Accepted. (IF2020 = 7.446)
2. Zhang T, Zhang R, Xu B, Zhang M, Zhang Q, Li N, Qiu Y, Chen D, Xu K, Xiao J, Zhang N*, Fang Q*. Spinal endomorphins attenuate burn-injury pain in male mice by inhibiting p38 MAPK signaling pathway through the mu-opioid receptor. European Journal of Pharmacology. 2021; 903:174139. (IF2020 = 4.432)
3. Zhang MN, Xu B, Li N, Liu H, Shi XR, Zhang QQ, Shi YB, Xu KT, Xiao J, Chen D, Zhu HW, Sun YL, Zhang T, Zhang R, Fang Q*. Synthesis and biological characterization of cyclic disulfide-containing peptide analogs of the multifunctional opioid/neuropeptide FF receptors agonist that produced long-lasting and nontolerant antinociception. Journal of Medicinal Chemistry 2020; 63(24), 15709-15725. (IF2020 = 7.446, 封面文章)
4. Xu B, Xiao J, Xu KT, Zhang QQ, Chen D, Zhang R, Zhang MN, Zhu HW, Niu JD, Zheng T, Li N, Zhang XY, Fang Q*. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Neuropharmacology 2020; 175: 108178. (IF2020 = 5.250)
5. Zhang R, Xu B, Zhang QQ, Chen D, Zhang MN, Zhao GH, Xu KT, Xiao J, Zhu HW, Niu JD, Li N*, Fang Q*. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. European Journal of Pharmacology. 2020; 880: 173169. (IF2020 = 4.432)
6. Xu B, Guo YY, Zhang MN, Zhang R, Chen D, Zhang QQ, Xiao J, Xu KT, Li N, Qiu Y, Zhu HW, Niu JD, Zhang XY*, Fang Q*. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist. Neurogastroenterology & Motility. 2020; 32(8): e13848. (IF2020 = 3.598)
7. Wang ZL, Xu B, Jiang CY, Zhang T, Zhang MN, Li N, Zhang QQ, Xu KT, Chen D, Xiao J, Fang Q*. Spinal DN-9, a peptidic multifunctional opioid/neuropeptide FF agonist produced potent nontolerance forming analgesia with limited side effects. Journal of Pain. 2020; 21(3-4): 477-493. (IF2020 = 5.820)
8. Xu B, Zhang MN, Shi XR, Zhang R, Chen D, Chen Y, Wang ZL, Qiu Y, Zhang T, Xu KT, Zhang XY, Liedtke W*, Wang R*, Fang Q*. The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via mu and kappa opioid receptors. British Journal of Pharmacology. 2020; 177: 93-109. (IF2020 = 8.739)
9.Zhang T, Han Z, Shi X, Zhao W, Wang Z, Zhang R, Xu B, Zhang M, Zhang Q, Xiao J, Zhu H, Zheng T, Fang Q*. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation. Bioorganic & Medicinal Chemistry. 2019; 27: 630-643. (IF2020 = 3.641)
10. 方泉，李宁，许彪，王锐* 多靶点肽类镇痛药物的研究进展，2019，43(10): 726-37
11. Zhang T1, Zhang N1, Zhang R, Zhao WD, Chen Y, Wang ZL, Xu B, Zhang MN, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Fang Q*. Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines. Journal of Neuroinflammation. 2018; 15: 320. (IF2020 = 8.322) (1: authors contributed equally to this work)
12. Zhang T, Zhao WD, Zhang MN, Xu B, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Zheng T, Fang Q*. Analgesic activities of the mixed opioid and NPFF receptors agonist DN-9 in a mouse model of formalin-induced orofacial inflammatory pain. Peptides. 2018; 110C: 30-39. (IF2020 = 3.750)
13. Chen C1, Xu B1, Shi XR, Zhang MN, Zhang QQ, Zhang T, Zhao WD, Zhang R, Wang ZL, Fang Q*. GpTx-1 and [Ala5, Phe6, Leu26, Arg28]GpTx-1, two peptide NaV1.7 inhibitors: analgesic and tolerance properties at the spinal level. British Journal of Pharmacology. 2018; 175(20): 3911-3927 (IF2020 = 8.739) (1: authors contributed equally to this work)
14. Li N, Han ZL, Xu B, Zhang MN, Zhang T, Shi XR, Zhao WD, Guo YY, Zhang QQ, Fang Q*. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain. European Journal of Pharmacology. 2018; 837: 53-63. (IF2020 = 4.432)
15. Wang P, Zheng T, Zhang MN, Xu B, Zhang R, Zhang T, Zhao WD, Shi XR, Zhang QQ, Fang Q*. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice. Brain Research Bulletin. 2018; 139:48-55. (IF2020 = 4.077)
16. Zheng T1, Zhang R1, Zhang T, Zhang MN, Xu B, Song JJ, Li N, Tang HH, Wang P, Wang R*, Fang Q*. CB1 cannabinoid receptor agonist mouse VD-hemopressin(α) produced supraspinal analgesic activity in the preclinical models of pain. Brain Research. 2018; 1680: 155-164. (IF2020 = 3.252)
17. Zhang R, Xu B, Zhang MN, Zhang T, Wang ZL, Zhao G, Zhao GH, Li N, Fang Q*, Wang R*. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model. European Journal of Pharmacology. 2017; 813:122-129. (IF2020 = 4.432)
18. Zheng T, Zhang T, Zhang R, Wang ZL, Han ZL, Li N, Li XH, Zhang MN, Xu B, Yang XL, Fang Q*, Wang R*. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobinderived peptide exhibiting cannabinoid agonist-like effects in mice. Neuropeptides 2017, 63: 83-90. (IF2020 = 3.286)
19. Wang ZL, Pan JX, Song JJ, Tang HH, Yu HP, Li XH, Li N, Zhang T, Zhang R, Xu B, Zhang MN, Fang Q*, Wang R*. Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent non-tolerance forming analgesic activities. Journal of Medicinal Chemistry. 2016; 59(22):10198-10208. (IF2020 = 7.446) 20. Yu HP, Zhang N, Zhang T, Wang ZL, Li N, Tang HH, Zhang R, Zhang MN, Xu B, Fang Q*, Wang R*. Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway. Peptides. 2016; 86: 24-32. (IF2020 = 3.750)
21. Li N1, Han ZL1, Wang ZL, Xing YH, Sun YL, Li XH, Song JJ, Zhang T, Zhang R, Zhang MN, Xu B, Fang Q*, Wang R*. BN-9, a chimeric peptide with mixed opioid and NPFF receptors agonistic properties, produces nontolerance-forming antinociception in mice. British Journal of Pharmacology. 2016; 173(11): 1864-1880. (IF2020 = 8.739) (1: authors contributed equally to this work) 22. Wang ZL1, Li N1, Wang P, Tang HH, Han ZL, Song JJ, Li XH, Yu HP, Zhang T, Zhang R, Xu B, Zhang MN, Fang Q*, Wang R*. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance. Neuropharmacology. 2016; 108: 364-372. (IF2020 = 5.250) (1: authors contributed equally to this work) 23. Chen Y, Fang Q, Wang Z, Zhang JY, MacLeod AS, Hall RP, Liedtke WB*. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch. Journal of Biological Chemistry. 2016; 291:10252-10262. (IF2020 = 5.157)
25. Zhang XY, Chen Y, Li Lin, Qiao H, Wang R, Ni JM *, You JQ, Ma KK, Fan CC, Fang Q. Development and validation of a reversed phase liquid chromatographic method with fluorescence detection for the pharmacokinetic study of a new chimeric peptide. Analytical Methods. 2016; 8(12): 2620-2627. (IF2020 = 2.896)
26. Pan JX1, Wang ZL1, Li N, Zhang N, Wang P, Tang HH, Zhang T, Yu HP, Zhang R, Zheng T, Fang Q*, Wang R*. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. European Journal of Pharmacology. 2015; 767(C):119-125. (IF2020 = 4.432) (1: authors contributed equally to this work) 27. Han ZL, Wang ZL, Li XH, Li N, Pan JX, Zheng T, Fang Q*, Wang R*. Neuropeptide VF enhances cannabinoid agonist WIN55,212-2-induced antinociception in mice. Anesthesia & Analgesia. 2015; 121(5):1360-1368. (IF2020 = 5.108)
28. Chen Y, Kanju P 2, Fang Q 2, Lee SH, Parekh PK, Lee W, Moore C, Brenner D, Gereau RW 4th, Wang F, Liedtke W*. TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor. Pain. 2014; 155(12):2662-72. (IF2020 = 6.961) (2: authors contributed equally to this work)
29. Han ZL1, Fang Q1, Wang ZL, Li XH, Li N, Chang XM, Pan JX, Tang HZ, Wang R*. Antinociceptive effects of central administration of the endogenous CB1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], a N-terminally extended hemopressin peptide. Journal of Pharmacology and Experimental Therapeutics. 2014; 348(2): 316-323. (IF2020 = 4.030) (1: authors contributed equally to this work)
30. Wang ZL1, Fang Q 1, Han ZL, Pan JX, Li XH, Li N, Tang HH, Wang P, Zheng T, Chang XM, Wang R*. Opposite Effects of Neuropeptide FF on Central Antinociception Induced by Endomorphin-1 and Endomorphin-2 in Mice. PLoS One. 2014; 9(8): e103773. (IF2020 = 3.240) (1: authors contributed equally to this work)
31. Pan JX, Wang ZL, Li N, Han ZL, Li XH, Tang HH, Wang P, Zheng T, Fang Q*, Wang R*. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Neuroscience Letters. 2014; 578: 187-191. (IF2020 = 3.046)
32. Li XH1, Li N1, Wang ZL, Pan JX, Han ZL, Chang XM, Tang HH, Wang P, Wang R*, Fang Q*. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats. Peptides. 2014; 56(C): 45-51. (IF2020 = 3.750)
33. Han ZL, Wang ZL, Tang HZ, Li N, Fang Q*, Li XH, Yang XL, Zhang XY, Wang R*. Neuropeptide FF attenuates the acquisition and the expression of conditioned place aversion to endomorphin-2 in mice. Behavioural Brain Research 2013; 248(1):51-56. (IF2020 = 3.332)
34. Sun YL, Zhang XY, He N, Sun T, Zhuang Y, Fang Q*, Wang KR, Wang R*. Neuropeptide FF activated ERK and NF kappa B signal pathways in differentiated SH-SY5Y cells. Peptides 2012; 38(1):110-117. (IF2020 = 3.750)
35. Li N 1, Han ZL 1, Fang Q*, Wang ZL, Tang HZ, Ren H, Wang R*. Neuropeptide FF and related peptides attenuates warm-, but not cold-water swim stress-induced analgesia in mice. Behavioural Brain Research 2012; 233(2): 428-433. (IF2020 = 3.332)
36. Fang Q, Han ZL, Li N, Wang ZL, He N, Wang R*. Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice. Neuropharmacology 2012; 62 (2): 855-864. (IF2020 = 5.250)
37. Fang Q 1, Jiang TN 1, Li N, Han ZL, Wang R*. Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice. Protein & Peptide Letters 2011; 18(4): 403-409. (IF2020 = 1.890) (1: authors contributed equally to this work)
38. Fang Q 1, Li N 1, Jiang TN, Liu Q, Li YL, Wang R*. Pressor and tachycardic responses to intrathecal administration of Neuropeptide FF in anesthetized rats. Peptides 2010; 31(4): 683-688. (IF2020 = 3.750) (1: authors contributed equally to this work)
39. Fang Q 1, Liu Q 1, Li N, Jiang TN, Li YL, Yan X, Wang R*. Cardiovascular effects of intravenous administered 26RFa, a novel RF-amide peptide ligand for GPR103, in anaesthetized rats. European Journal of Pharmacology 2009; 621(1-3): 61-66. (IF2020 = 4.432) (1: authors contributed equally to this work)
40. Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R*. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regulatory Peptides 2008; 147(1-3): 45-51. (SCI, IF2008 = 2.276)
41. Fang Q, Zhang BZ, Wang R*. Progress in the structure-activity relationship studies of neuropeptide FF. Progress in Chemistry 2007; 19: 1977-1985. (IF2020 = 1.172, Review, in Chinese)
42.F ang Q, He F, Wang YQ, Guo J, Zhang BZ, Chen Q, Wang R*. Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides 2007; 41(5): 339-347. (IF2020 = 3.286)
43. Fang Q, Guo J, He F, Peng YL, Chang M, Wang R*. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 2006; 27(9): 2207-2213. (IF2020 = 3.750)
44. Fang Q, Guo J, Peng YL, Chang M, He F, Chen Q, Wang R*. In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides 2006; 27(6): 1297-1304. (IF2020 = 3.750)
45. Fang Q, Guo J, Chang M, Chen LX, Chen Q, Wang R*. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides 2005; 26(5): 791-797. (IF2020 = 3.750)
46. Chen LX , Fang Q, Chen Q, Guo J, Wang ZZ, Chen Y, Wang R. Study in vitro and in vivo of nociceptin/orphanin FQ(1-13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3. Peptides 2004; 25(8): 1349-1354. (IF2020 = 3.750)
47. Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R*. Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides 2008; 29(7): 1183-90. (IF2020 = 3.750)48. Chen LX, Wang ZZ, Wu H, Fang Q, Chen Y, Guo J, Chen Y, Wang R*. Effects of nociceptin (13-17) in pain modulation at supraspinal level in mice. Neuroscience Letters 2002; 331(2): 95-98. (IF2020 = 3.046)
49. Wang YQ, Wang SB, Ma JL, Guo J, Fang Q, Sun T, Zhuang Y, Wang R*. Neuropeptide FF receptor antagonist, RF9, attenuates the fever induced by central injection of LPS in mice. Peptides. 2011; 32(4): 702-706. (IF2020 = 3.750)
50. Sun YL, Zhang XY, Sun T, He N, Li JY, Zhuang Y, Fang Q, Wang R. The anti-inflammatory potential of neuropeptide FF in vitro and in vivo. Peptides 2013; 47:124-132. (IF2020 = 3.750)
51. Sun YL, Sun T, Zhang XY, He N, Zhuang Y, Li JY, Fang Q, Wang KR, Wang R*. NPFF2 receptor is involved in the modulatory effects of neuropeptide FF for macrophage cell line. Protein & Peptide Letters 2014; 21(5): 490-502. (IF2020 = 1.890)
52. Fang Q, Yang MJ，Li RD. Inhibitory effects of melation on the tumor in mice bearing S180. Chinese Pharmacological Bulletin 2003; 2: 234-235. (in Chinese) （国内核心）
53. Fang Q, He F, Wang YQ, Chen Q, Wang R. Studies in vitro and in vivo of pharmacological activities of PFR(Tic)amide. Sciencepaper Online (http://www.paper.edu.cn) 2006 Nov. 30. （科技论文在线）
54. 李 宁，方 泉*. RFa家族新成员26RFa/43RFa的研究进展. 中国科技论文在线, http://www.paper.edu.cn/index.php/default/releasepaper/content/201202-2, 2012- 02-01（科技论文在线，四星级论文）
参编书籍：
王 锐，方 泉，张 伟。参编中国科协组织2012-2013年的《生物化学与分子生物学学科发展报告》的“多肽学科发展报告”部分——“多肽科学研究进展”，中国科学技术出版社。
代表性专利成果：
1. 王 锐，方 泉，李 宁，韩政岚；“基于内吗啡肽2和神经肽FF的嵌合肽及其合成和应用”， 国家发明专利，授权号：ZL201110097843.4，申请日期：2011年4月19日；公 开 (公告) 号： CN102206285A，公开(公告)日： 2011.10.05。授权日期：2013年2月13日
2. 王 锐，方 泉，韩政岚，王子龙，李宁；“基于阿片肽Biphalin和神经肽FF的嵌合肽及其合成和应用”，国家发明专利，授权专利号：ZL201210098832.2，授权日期：2014年5月21日。已申请国际专利，PCT/CN2013/070611
3. 王 锐，方 泉，韩政岚，王子龙，李宁，李旭辉；“内源性大麻肽类激动剂(m)VD-Hpα在制备镇痛药物中的应用”，国家发明专利，授权专利号：ZL201310087565.3，授权日期：2015年4月22日。
4. 王 锐，方 泉，李 宁，韩政岚，王子龙；“基于内吗啡肽2和NPFF受体拮抗剂RF9的分叉型杂交肽及其合成方法和应用”，国家发明专利，专利号： ZL201510123629.X，授权日期：2017年11月28日
5. 王 锐，方 泉，王 沛，张 婷，王子龙，李宁；“基于内吗啡肽2或Biphalin的棕榈酰化修饰的阿片肽类似物及其合成和应用”， 国家发明专利，授权专利号： ZL201510619850.4，授权日期：2018年5月1日
